News & Updates
Filter by Specialty:
Psoriasis patients with overweight, obesity may need higher vunakizumab dosage
In the treatment of moderate-to-severe psoriasis, patients with overweight or obesity appear to have a diminished response to vunakizumab compared with those who have lower BMIs, according to a post hoc subgroup analysis of a phase III trial.
Psoriasis patients with overweight, obesity may need higher vunakizumab dosage
14 Oct 2024
Ebdarokimab works wonders for patients with plaque psoriasis
A recent study has shown the safety and efficacy of AK 101 (ebdarokimab) in the treatment of patients with plaque psoriasis, achieving ≥75-percent improvement in Psoriasis Area and Severity Index (PASI 75) and Static Physicians Global Assessment (sPGA) 0/1 response.
Ebdarokimab works wonders for patients with plaque psoriasis
14 Oct 2024
MARIPOSA update: Amivantamab-lazertinib bests osimertinib for EGFRm NSCLC at 3 years
The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).
MARIPOSA update: Amivantamab-lazertinib bests osimertinib for EGFRm NSCLC at 3 years
14 Oct 2024
Risankizumab eases symptoms in nonpustular palmoplantar psoriasis
In patients with nonpustular palmoplantar psoriasis (nPPP), treatment with risankizumab relieves disease symptoms, such as skin pain in palms or soles of feet, by week 16, as shown by the results of a post hoc analysis of the phase IIIb IMMprint study. These improvements persist up to week 52.